{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T14:30:35Z","timestamp":1648909835235},"reference-count":60,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["revespcardiol.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.rec.2014.01.012","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T02:02:02Z","timestamp":1398909722000},"page":"480-487","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Antiplatelet Therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Paul A.","family":"Gurbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahil","family":"Rafeedheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2014.01.012_bib0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0010","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1586\/14779072.2013.839382","article-title":"Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account","volume":"11","author":"Tantry","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.rec.2014.01.012_bib0020","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","article-title":"Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents","volume":"125","author":"Gurbel","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erc.13.20","article-title":"Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease","volume":"11","author":"Tantry","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.rec.2014.01.012_bib0030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/clpt.2010.316","article-title":"Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions","volume":"89","author":"Beitelshees","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rec.2014.01.012_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rec.2014.01.012_bib0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0045","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0050","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rec.2014.01.012_bib0055","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.rec.2014.01.012_bib0060","first-page":"1","article-title":"The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors","volume":"12","author":"Price","year":"2011","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.rec.2014.01.012_bib0065","unstructured":"Plavix\u00ae [package insert] [cited 2014 Jan 10]. Available from: www.Plavix.com"},{"key":"10.1016\/j.rec.2014.01.012_bib0070","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FJC.0b013e3181ffe8d0","article-title":"The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity","volume":"57","author":"Lau","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rec.2014.01.012_bib0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2013.03.037","article-title":"The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: The PARADOX Study","volume":"62","author":"Gurbel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0090","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2012.5930","article-title":"Clopidogrel efficacy and cigarette smoking status","volume":"307","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/eurheartj\/ehr458","article-title":"Toward a therapeutic window for antiplatelet therapy in the elderly","volume":"33","author":"Gurbel","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rec.2014.01.012_bib0115","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0120","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","article-title":"2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non\u2013ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0125","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rec.2014.01.012_bib0130","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0135","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0140","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rec.2014.01.012_bib0145","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2011.332","article-title":"An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial","volume":"305","author":"Gurbel","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0150","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0160","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0170","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"Campo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","article-title":"Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study","volume":"1","author":"Cuisset","year":"2008","journal-title":"J Am Coll Cardiol Interven"},{"key":"10.1016\/j.rec.2014.01.012_bib0180","first-page":"614","article-title":"ADAPT-DES Investigators","volume":"382","author":"Stone","year":"2013","journal-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet"},{"key":"10.1016\/j.rec.2014.01.012_bib0185","article-title":"New insights into high platelet reactivity and the existence of a therapeutic window: ADAPT-DES at 2 years","author":"Kirtane","year":"2014","journal-title":"Presented at TCT 2013 [cited 2014 Jan 24]"},{"key":"10.1016\/j.rec.2014.01.012_bib0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation After Deployment of Intracoronary Stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rec.2014.01.012_bib0195","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1538-7836.2010.04063.x","article-title":"Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study","volume":"8","author":"Fontana","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rec.2014.01.012_bib0200","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rec.2014.01.012_bib0210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ahj.2010.05.034","article-title":"Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events","volume":"160","author":"Gurbel","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.rec.2014.01.012_bib0215","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rec.2014.01.012_bib0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2013.7155","article-title":"Generic clopidogrel: time to substitute?","volume":"310","author":"Doll","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rec.2014.01.012_bib0225","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2012.10.020","article-title":"Bioequivalence in the real world is a complex challenge: the case of clopidogrel","volume":"61","author":"Marcucci","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0230","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.clinthera.2010.08.001","article-title":"Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study","volume":"32","author":"Shim","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.rec.2014.01.012_bib0235","first-page":"640","article-title":"The impact of generic form of clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study","volume":"16","author":"Khosravi","year":"2011","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.rec.2014.01.012_bib0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FJC.0b013e31827e5c60","article-title":"Branded versus generic clopidogrel in cardiovascular diseases: a systematic review","volume":"61","author":"Caldeira","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rec.2014.01.012_bib0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e31826f36bc","article-title":"A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel","volume":"60","author":"Sambu","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rec.2014.01.012_bib0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1074248413510605","article-title":"Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel","volume":"19","author":"Kovacic","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.rec.2014.01.012_bib0255","article-title":"Prevalence of free methyl chloride as an impurity in generic clopidogrel preparations. Safety implications in cardiovascular patients","volume":"122","author":"Wahi","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.rec.2014.01.012_bib0260","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","article-title":"Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction","volume":"122","author":"Heestermans","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.rec.2014.01.012_bib0265","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"6","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.rec.2014.01.012_bib0270","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0275","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","article-title":"Morphine decreases clopidogrel concentrations and effects: a randomized, double blind, placebo-controlled trial","volume":"63","author":"Hobl","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0280","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2004.02.019","article-title":"Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting","volume":"128","author":"Chen","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.rec.2014.01.012_bib0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCINTERVENTIONS.111.967208","volume":"5","author":"Mahla","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.rec.2014.01.012_bib0290","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2010.03.108","article-title":"Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery","volume":"56","author":"Kwak","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rec.2014.01.012_bib0295","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.athoracsur.2010.09.022","article-title":"Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines","volume":"91","author":"Ranucci","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.rec.2014.01.012_bib0300","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.athoracsur.2012.07.086","article-title":"Society of Thoracic Surgeons 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations","volume":"94","author":"Ferraris","year":"2012","journal-title":"Ann Thorac Surg"}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585714001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585714001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:56:51Z","timestamp":1538647011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585714001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1885585714001157"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2014.01.012","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Antiplatelet Therapy","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2014.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2014.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}